Eli Lilly and Retatrutide (LY3437943)
Retatrutide is the Eli Lilly compound designated LY3437943. The company published the original tri-agonist characterisation and sponsors the registered trial programme.
Key concepts
- LY3437943 and retatrutide are the same molecule
- Eli Lilly published the original tri-agonist characterisation
- Phase 2 results are peer-reviewed; later studies are registered
- Research supply is unaffiliated with the sponsor
- Sponsorship is directly checkable across paper, registry and pipeline page
- Sponsor involvement does not imply approval or extend to third-party research supply
From LY3437943 to retatrutide
Internal compound codes prefixed LY belong to Eli Lilly, and LY3437943 is the code under which retatrutide first appeared in the literature. The 2022 Cell Metabolism paper describing it as a triple glucagon, GIP and GLP-1 receptor agonist is the primary reference for its receptor pharmacology, and later publications use the non-proprietary name.
Seeing both designations used interchangeably in the literature is normal; they refer to the same molecule.
Where the programme sits
Published results include phase 2 data in peer-reviewed journals, with later-stage studies registered on public trial registries. That places retatrutide in active clinical investigation, which is a different thing from regulatory approval.
| Source | What it tells you |
|---|---|
| Cell Metabolism, 2022 | In-vitro and preclinical receptor characterisation of LY3437943 |
| N Engl J Med, 2023 | Peer-reviewed phase 2 results in obesity research |
| ClinicalTrials.gov | Current registered studies, phases, status and endpoints |
| Lilly pipeline disclosures | Company statement of development stage |
No relationship with research supply
Biovanta Research has no affiliation with Eli Lilly and Company. The peptide we supply is research-grade material for in-vitro use and is not a Lilly product; references to the company here exist only because its publications are the scientific record for the molecule.
Retatrutide supplied by Biovanta Research is laboratory material for in-vitro research by qualified persons. It is not a medicine, not for human or veterinary use, and no dosing guidance is given.
How to verify Eli Lilly’s involvement directly
Rather than relying on a secondary description, a laboratory can confirm the sponsor’s role directly: the Cell Metabolism paper lists Eli Lilly-affiliated authors and funding, ClinicalTrials.gov records list Eli Lilly and Company as sponsor for the relevant studies, and the company’s own pipeline page lists the compound by name and phase. Cross-checking two or more of these sources is a reasonable standard before repeating a sponsorship claim elsewhere.
It is worth noting that sponsor pipeline pages are updated periodically and describe the company’s own characterisation of development stage; they should be read alongside, not instead of, the independently registered trial records.
What the sponsor’s role does and does not establish
Sponsorship establishes who is responsible for the design, conduct and reporting of the registered studies, and who holds the underlying data package that would eventually support a regulatory submission. It does not establish that the compound is approved, that any specific benefit is established outside the trial population studied, or that research-grade material sold elsewhere carries any of the sponsor’s quality assurances.
How the UK and US regulatory position differs for this programme
Eli Lilly’s registered studies run across multiple jurisdictions, and the regulatory question for each is answered separately: US status is checked against the FDA’s Drugs@FDA database, and UK status is checked against the MHRA products register. Both currently show retatrutide as unapproved and investigational, but the two registers are independent and a change in one does not automatically imply a change in the other, since each regulator conducts its own review of the same underlying data package on its own timetable.
A laboratory or reader interested in tracking the programme’s regulatory progress should therefore check both registers directly, rather than assuming that an announcement about one jurisdiction applies equally to the other.
What a laboratory should record when citing this programme
When a laboratory report references the Eli Lilly programme as background, it is good practice to cite the specific paper or registry record used, including its publication date or last-verified date, rather than citing the programme in general terms. This matters because trial status, phase and enrolment details change over time, and a citation that is not dated can become misleading well before the underlying document is formally superseded.
Reading Eli Lilly’s own disclosures critically
Company pipeline pages and investor disclosures describe development stage from the sponsor’s own perspective and are updated on the company’s own schedule, so they should be read as one input among several rather than as the sole source. Cross-checking a pipeline statement against the independently maintained ClinicalTrials.gov record for the same compound is a reasonable way to confirm that a stated phase or status is current rather than superseded.
Strength of the current evidence
All statements here are drawn from published papers, public trial registry entries and company pipeline disclosures, each of which can be checked independently by a reader.
References
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med, 2023 (DOI)
- Eli Lilly and Company research and development pipeline (Eli Lilly)
- Retatrutide studies sponsored by Eli Lilly and Company (ClinicalTrials.gov search listing)
Related Retatrutide research
- Who Makes Retatrutide? — Who develops retatrutide as an investigational compound, and who manufactures the peptide sold as research material.
- Published Research — An overview of the peer-reviewed retatrutide research record, from receptor pharmacology to phase 2 trials.
- Is Retatrutide Approved? — Current regulatory status of retatrutide: investigational, not approved as a medicine in the UK, US or EU.
Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.